Biology

Microbiology & Immunology fields

Okayama University

Year~2003

Neutrophil and lymphocyte responses to oral Streptococcus in Adamantiades-Behcet's disease

Tomomi Kurauchi^{*} Kenji Yokota[†] Toshihiko Matsuo[‡] Yoshihito Fujinami^{**} Emiko Isogai^{††} Hiroshi Isogai^{‡‡} Hiroshi Ohtsuki[§] Keiji Oguma[¶]

*Okayama University

[†]Okayama University, yokochan@md.okayama-u.ac.jp

[‡]Okayama University

**Okayama University

^{††}University of Hokkaido

 $^{\ddagger\ddagger} \mathrm{Sapporo}$ Medical University

[§]Okayama University

¶Okayama University

This paper is posted at eScholarship@OUDIR : Okayama University Digital Information Repository.

http://escholarship.lib.okayama-u.ac.jp/microbiology_and_immunology/5

Neutrophil and lymphocyte responses to oral streptococcus in Adamantiades-Behçet's disease

Tomomi Kurauchi^{a, b}, Kenji Yokota^a, Toshihiko Matsuo^a, Yoshihito Fujinami^b, Emiko

5 Isogai^c, Hiroshi Isogai^d, Hiroshi Ohtsuki^a, and Keiji Oguma^b

^aOphthalmology, ^b Bacteriology

Okayama University Graduate School of Medicine and Dentistry.

2-5-1 Shikatacho Okayama 700-8558, JAPAN.

10 °Preventive Dentistry, Health Sciences University of Hokkaido Ishikari-Tobetsu 1757, Hokkaido 061-0293, JAPAN.

^d Division of Animal Experimentation, Sapporo Medical University

Minami 1 Nishi 17 Chuo-ku Sapporo 060-0061, JAPAN.

Corresponding author

15 Kenji YOKOTA Ph.D.

Bacteriology, Okayama University Graduate School of Medicine and Dentistry.

2-5-1 Shikatacho Okayama 700-8558, JAPAN.

Tel +81-86-235-7158

Fax +81-86 235-7162

20 E-mail; yokochan@md.okayama-u.ac.jp

Abstract

Immune reactions against microorganisms play an important pathogenic role in Adamantiades-Behçet's disease (ABD). We had previously obtained *Streptococcus sanguinis* (strain BD113-20) isolated from the oral cavity of patients with ABD. To

- 5 investigate the pathogenesis of this isolate, we examined neutrophil reactions and level of cytokine production by lymphocytes after stimulation with the strain. The reactions of neutrophils were examined by chemiluminescence assay using whole blood. The amounts of interferon gamma (IFN-γ) and interleukin (IL)-4, IL-8, IL-10, and IL-12 produced by peripheral blood mononuclear cells (<u>PBMCs</u>) were measured by ELISA.
- Strain BD113-20 activated neutrophils from patients with ABD and healthy volunteers, and, in addition it increased IFN-γ production by lymphocytes. Lymphocyte from the patients with ABD showed a dominant T helper 1 (Th-1) immune response. Results indicated that both bacterial stimulation and host hypersensitivity might be involved in the symptoms and pathogenesis of ABD.
- 15 Key words

Adamantiades-Behcet's disease, *Streptococcus sanguinis*, neutrophil, chemiluminescence, IL-8, T helper-1, IFN-γ, IL-12

1. Introduction

Adamantiades-Behçet's disease (ABD) is a multi-system disorder that presents with recurrent oral and genital ulceration as well as uveitis, leading sometimes to blindness. Although the etiology and pathogenesis of this disease remain obscure,

- 5 different bacteria and viruses have been suggested as causative factors. Several investigators have reported that streptococcal infection is related to the onset of ABD. Patients with ABD have shown significantly higher incidences of tonsillitis and dental caries, probably due to streptococci, and the lymphocytes obtained from such patients were sensitive to streptococcal antigens [1, 2]. Additionally, patients with ABD showed
- 10 hypersensitivity in skin tests to streptococcal antigens [3]. We have previously shown that the proportion of *Streptococcus sanguinis* (strain BD113-20 isolated from a patient with ABD) in the oral flora of patients with ABD was significantly higher than in controls [4], and the serum anti-BD113-20 titers of the patients were also higher than titers to standard strains [5]. In another study, patients' sera did not neutralize bacterial
- IgA protease purified from BD113-20, demonstrating that humoral immunity against oral streptococci in patients with ABD was not sufficient to exclude the oral bacteria [6].
 Taken together, these results suggest that both host immunity and oral bacteria are involved in the pathogenesis of ABD.
- In this study, we demonstrate the neutrophil and lymphocyte reactions against *S*. 20 *sanguinis* BD113-20 isolated from patients with ABD. Neutrophil reactions were examined by chemiluminescence (CL) assay using whole blood stimulated with streptococcal antigens and zymozan. Peripheral blood mononuclear cells (PBMCs) were also stimulated with streptococcal antigens, and their T helper 1- and 2-associated cytokines were investigated.

2. Materials and Methods

2.1. Patients

Nineteen patients with ABD (8 men and 11 women; aged 32 to 79, mean 55.8 years), diagnosed according to the international study group criteria were studied.

- 5 Historical information of 19 patients with ABD is shown in Table 1. Clinical information at the time of drawing blood is also shown in Table 2. Twenty-one healthy volunteers (11 men and 10 women; aged 21 to 41, mean 30.8 years) were used as controls. Heparinized blood was obtained of which a portion was used for neutrophil examination within 2 hours. The remaining heparinized peripheral blood was layered on
- 10 a Ficoll-Paque density gradient solution and centrifuged (3000xg, 30 min). The upper layer, containing plasma and platelets, was removed, and the buffy coat, the rich fraction in peripheral mononuclear cells (PBMCs) collected. The PBMCs were washed twice with phosphate buffered saline (PBS, pH 7.2) and cultured in RPMI1640 medium containing 10% fetal calf serum (FCS).
- 15 2.2. Bacterial strains

Streptococcus sanguinis strain BD113-20, isolated from the mouths of patients with ABD, was employed. *Streptococcus pyogenes* (WHO-T type 12), *Streptococcus salivarius* (ATCC 7073), and *Streptococcus sanguinis* (ATCC 10556) were also used as control strains. All strains were cultured in Todd-Hewitt broth (Difco, Detroit, MI) at

20 37C for 18 hr. The cells were harvested by centrifugation (6,000xg, 20 min, 4 C) and washed three times with 10 mM PBS. The whole cells were disrupted with <u>a Branson</u> cell homogenizer (Branson model 250 sonifier, Branson Ultrasonices, Danbury, CN), and the unbroken cells were removed by centrifugation (6,000xg, 20 min, 4 C). The supernatants were again centrifuged at high speed (20,000xg, 30 min, 4 C), and the

resulting supernatants were designated as the 20S antigen.

2.3. Chemiluminescence (CL) assay

Neutrophil activity was measured using a CL assay. Heparinized blood (100 μ l) was suspended in 400 μ l of Hanks solution with 20 mM HEPES and 10mM CaCl2 (pH

7.4, HEPES-Hanks). The blood in the HEPES-Hanks solution was added to 10 μl of luminol solution (2 mg ml⁻¹), and then stimulated with 50 μl of streptococcal antigens (10mg ml⁻¹) or non-opsonized zymozan (5 mg ml⁻¹). The antigens' CL was immediately measured with a luminometer (Biolumat LB9505, Berthord, Germany).

2.4. Measuring Cytokine production levels

10 PBMCs (1x10⁶ cells ml⁻¹) were washed three times <u>in RPMI 1640 by</u> <u>centrifugation. Aliquot of 500 µl of cell suspentions were cultured in a 48 well plate</u> stimulated with the bacterial antigen of *S. sanguinis* (ATCC10556), BD113-20 (10 µg ml⁻¹), or <u>concanavalin</u> A (5 µg ml⁻¹: conA). Culture supernatants were collected at one week, and stored at –80 C. IFN-γ, IL-4, IL-8, IL-10 and IL-12 levels were measured

15 using an ELISA kit (Biosource, Camarillo,CA) <u>according to the</u> manufacturer's instructions.

2.5. Statistical analysis

20

Results were expressed as means + standard error (SE). Data were compared using <u>a Student's t-test</u>, and statistical differences were considered significant if p values were <0.05.

3. Results

3.1. Neutrophil activation

<u>BD113-20 was isolated from a patient with ABD and used to assess stimulation</u> of neutrophils in a CL assay. The stimulation by BD113-20 was significantly greater

5 (p<0.05) in both ABD and control subjects than was observed for other Streptococcus antigens or by zymosan (Fig. 1). CL in patients with ABD was also activated by the S. sanguinis type-strain (ATCC10556). However, on stimulation with S. pyogenes, CL did not differ between patients and controls. In the healthy volunteers, stimulation with S. salivarius induced strong CL activity. These results indicate that in the ability to activate

10 neutrophils, BD113-20 may differ from other oral streptococcci.

Stimulation with strain BD113-20 induced high levels of IL-8 production by PBMCs in both the patients (867+55 ng ml⁻¹) and the controls (599+82 ng ml⁻¹) (Fig. 2). Also, the level of production was significantly (p=0.027) higher in the patients with ABD than controls. The *S. sanguinis* type-strain did not induce IL-8 production either in

- 15 patients with ABD or in controls. Infection with BD113-20 in patients with ABD may enhance neutrophil activation.
 - 3.2. Levels of Th-1/2-associating cytokines

Stimulation with BD113-20 induced high levels of IFN- γ production from PBMCs of patients with ABD (2254+238 pg ml⁻¹) and controls (2301+399 pg ml⁻¹) (Fig.

3). The type-strain of *S. sanguinis* (ATCC10556) induced IFN-γ (1075+249 pg ml⁻¹) production by PBMCs from the patients with ABD, however little IFN-γ (125+69 pg ml⁻¹) was produced by lymphocytes <u>from</u> controls.

The type strain of *S. sanguinis* (ATCC10556) and BD113-20 induced a high level of production of IL-12 (*S. sanguinis* (ATCC10556) stimulation; 1975+410 pg ml⁻¹,

BD113-20 stimulation; 2540+430 pg ml⁻¹) by PBMCs of the patients (Fig. 4). On stimulation with any antigen, IL-12 production from PBMCs from patients with ABD was significantly increased compared to that by PBMCs of controls.

Levels of Th-2 <u>associated</u> cytokines (IL-4 and IL-10) were low. Specifically,
Iittle IL-4 was detected in PBMCs of patients with ABD or controls (data not shown).
Stimulation with the *S. sanguinis* type-strain (ATCC10556) induced significant IL-10 production (130+34 pg ml⁻¹) from PBMCs in patients with ABD (Fig. 5), while conA stimulation did not enhance IL-10 secretion from PBMCs. On the other hand, the healthy volunteers' PBMCs produced IL-10 following stimulation with BD113-20

10 (95+33 pg ml⁻¹) and conA (72+33 pg ml⁻¹). For PBMCs from controls, the IL-10 level, without stimulation, was below the detection limit. These results indicate that patients with ABD have a Th-1 dominant immunity, and infection with BD113-20 might enhance the Th-1 immune reaction.

3.3 Disease activity

15 <u>The mean age when first symptoms arose in the patients was 36.7 years old,</u> and 12 of 19 patients (63.5%) had developed aphthous stomatitis as a first symptom (Table 1). Disease activity of each patient <u>is</u> shown in Table 2. The CL and production of cytokines were not associated with active or inactive symptoms (Data not shown).

4. Discussion

5

Immunopathogenic mechanisms are closely associated with the etiology of ABD. Both microbial antigens and host immune responses may contribute to this multisystemic disorder, presenting various symptoms [7]. We have previously reported that *S. sanguinis* BD113-20 isolated from a patient with ABD, may be an important bacterium stimulating host immunity [4, 5, 6]. In this study, neutrophil reactions and T helper (Th-) 1 or 2 immunity-associated lymphokines were examined using soluble antigens of the strain.

Neutrophil activation is involved in the pathogenesis of ABD, as evidenced by
the lesions that are characteristic of neutrophil infiltration of the pustular folliculitis and
hypopyon [8]. It has been reported that neutrophil reactions were associated with some
viridans *Streptococcus* or group B *Streptococcus* [9, 10]. In this study, we found that
BD113-20 significantly enhanced CL activity in neutrophils, and may be different from
other oral streptococci. In addition, as a host factor, IL-8 was produced at high levels by
lymphocytes of patients with ABD than healthy volunteers. High levels of expression of
IL-8 mRNA in patients with ABD have also been reported [11, 12], and IL-8 seems to

be a reliable marker for disease activity [13]. Neutrophil activation may be promoted by the IL-8 released from lymphocytes and/or endothelial cells of patients with ABD. *Streptococcus* exists as oral flora in patients with ABD, whose symptoms may often be

20 caused by dental treatment or aphthous stomatitis.

Throughout life, viridans streptococci comprise a large proportion of the commensal microbiota in the oral cavity and pharynx [14], and different species of viridans streptococci are known to colonize distinct habitats within the mouth [15]. Uncommon streptococcus strains, such as strain BD113-20, were increased in oral flora

of patients with ABD [16], and were not eradicated by IgA mucosal immunity [6]. Both persistent infection by the neutrophil-activating *Streptococcus* and the lymphocyte responses are presumed to play an important role in the symptoms of ABD.

- Long-term bacterial stimulation will induce adaptive immunity in patients with 5 ABD. T-cell activation, both in the peripheral blood and in tissue specimens, occurs in ABD. The CD4-positive cells are divided into Th-1 and Th-2 cells. The differential effects of Th-1 and Th-2 populations are mediated through their characteristic cytokines. IL-12 is produced by macrophages and is a potent inducer of IFN-γ production by Th-1 cells and natural killer cells. IL-12, in concert with the presentation of antigens by
- 10 dendritic APC, is believed to promote the induction of CD4 positive T_{DTH} cells and T_{CTL} cells, thus directing the immune response to cell-mediated immunity. IL-12 production was significantly increased with or without stimulation in lymphocytes from patients with ABD. Numbers of IFN- γ and IL-2-producing T cells were increased in peripheral blood from patients with ABD, and were correlated with disease activity [16, 17]. High-
- 15 level production of IFN-γ was also induced by BD113-20. Bacterial stimulation may enhance Th-1 cell-mediated immunity in patients with ABD, resulting in the progression of chronic inflammation. We are now studying mechanisms by which production of IFN-γ and IL-12 is induced by BD113-20.

IL-10 is secreted from Th-2 cells, and it down-regulates Th-1 immunity and inflammation. IL-10 production in the patients and controls was at a low level and variable. We recognized no clear tendency in IL-10 production. IL-4 is also produced by Th-2 cells, however its level was below the detection limit in this study. Serum IL-4, IL-10, and IL-13 levels in patients with ABD were detectable but the pathogenic roles of Th-2-associating cytokines are still not clear [18, 19]. Our study indicates that the Th-2

humoral immunity against oral *Streptococcus* may be diverse in individuals, and it may not be effective for a case of stimulation with streptococcal antigens. On the other hand, autoantibodies against heat shock <u>proteins</u> (65kDa and ab-crystallin), which may be induced by bacterial stimulation, and endothelial cells have been detected in patients

5 with ABD [20,21,22]. Although humoral immunity may play an important pathogenic role in ABD, any association with bacterial stimulation and <u>the induction</u> of autoantibodies is still obscure.

Some papers indicated that cytokine profiles in serum and/or production from PBMC are different in disease activity [18, 23]. PBMC from patients with ABD

- 10 produced higher levels IL-4, IL-10, and IL-13, and the additions of IFN- γ to the anti-CD3 stimulated PBMC changed Th-1/Th-2 pattern with enhanced IL-12 and decreased IL-4 and IL-10 production [19]. Number of cell spontaneously secreting IFN- γ , IL-12, and TNF- α were increased in patients with active ABD [23]. In contrast, our result indicated that cytokine pattern was not different in the inactive and active patients.
- 15 Some researchers in the Japanese Behçet's disease committee reported that PBMCs from patients were already activated *in vivo* by some antigen. They reported that lymphocytes had been produced IL-8 or TNF for 1-2 days without stimuli (personal communication). Other papers also indicated that lymphocytes from patients with ABD were activated by some antigens *in vivo*. To eliminate the influence of original stimuli in
- 20 <u>the patients, PBMCs were washed three times and cultured for one week in this study.</u> <u>The PBMC from both inactive and active patients was produced high IL-8 and Th-1</u> <u>associated cytokines. The immunological future against antigen stimulations may be</u> <u>important for host factor of induction of ABD.</u>

In conclusion, S. sanguinis (BD113-20) isolated from a patient with ABD had

the capacity to stimulate activated neutrophils. Lymphocytes from patients with ABD showed high levels of production of IL-8, IFN- γ and IL-12 due to the neutrophil-activating bacteria. This study suggests that both bacterial stimulation and host hypersensitivity are involved in the symptoms and pathogenesis of ABD.

5

Acknowledgement

We are grateful to Dr. Lynn A Woodward of James Cook University, Australia for preparing the manuscript.

References

- [1] Aoki, K., Choo. S. (1972) Studies on the construction and past history of patients with Behçet's disease. Acta. Soc. Ophthalmol. 76, 1608-1612.
- [2] Martin D.K., Nelms D.C., Mackler B.F., Peavy D.L. (1979) Lymphoproliferative
- responses induced by streptococcal antigens in recurrent aphthous stomatitis andBehçet's syndrome. Clin. Immunol. Immunopathol. 13, 146-155.
 - [3] The Behçet's Disease Committee of Japan. (1989) Skin hypersensitivity to Streptococcus antigens and the induction of symptoms by the antigens in Behçet's disease. J Rheumatol. 16, 506-511.
- [4] Isogai, E., Ohno, S., Takeshi, K., Yoshikawa, K., Tsurumizu, T., Isogai, H., Yokota,
 K., Kotake, S., Sakamoto, Y., Shimizu, H., Matsuda, H., Yamaguchi, M., and
 Oguma, K. (1990) Close association of *Streptococcus sanguis* uncommon serotypes
 with Behçet's disease. Bifidobacteria Microflora. 9, 27-41.
 - [5] Yokota K, Hayashi S, Fujii N, Yoshikawa K, Kotake S, Isogai E, Ohno S, Araki Y,
- and Oguma K. (1992) Antibody response to oral streptococci in Behçet's disease.Microbiol. Immunol. 36, 815-822.
 - [6] Yokota K, and Oguma K. (1997) IgA protease produced by *Streptococcus sanguis* and antibody production against IgA protease in patients with Behçet's disease. Microbiol. Immunol. 41, 925-931.
- [7] Direskeneli, H. (2001) Behçet's disease: infections aetiology, new autoantigens, and HLA-B51. Ann. Rheum. Dis. 60, 996-1002.
 - [8] Sakane T, Takeno M, Suzuki N, Inada G, (1999) Behçet's disease. N. Eng. J Med.341, 1284-1291.
 - [9] Doran, K.S., Chang , J.C., Benoit, V.M., Eckmann, L., and Nizet ,V. (2002) Group B

Streptococcal beta-hemolysin/cytolysin promotes invasion of human lung epithelial cells and the release of interleukin-8. J Infect. Dis. 185:196-203.

- [10] Wanahita, A., Goldsmith, E.A., Musher, D.M., Clarridge III, J.E., Rubio, J., Krishnan, B., and Trial, J. (2002) Interaction between human polymorphonuclear
- leukocytes and Streptococcus milleri group bacteria. J Infect. Dis. 185, 85-90.
 - [11] Mantas, C., Direskeneli, H., Oz, D., Yavuz, S., Akoglu, T. (2000) IL-8 producing cells in patients with Behçet's disease. Clin Exp Rheumatol 18, 249-251.
 - [12] Zouboulis, C.C., Katsantonis, J., Ketteler, R., Treudler, R., Kaklamani, E., Hornemann, S., Kaklamanis, P., Orfanos, C.E. (2000) Adamantiades-Behçet's
- 10 disease: interleukin-8 is increased in serum of patients with active oral and neurological manifestations and is secreted by small vessel endothelial cells. Arch Dermatol Res. 292, 279-284.
 - [13] Katsantonis, J., Adler, Y., Orfanos, C.E., Zouboulis, C.C. (2000) Adamantiades-Behçet's disease: serum IL-8 is a more reliable marker for disease activity than C-
- 15 reactive protein and erythrocyte sedimentation rate. Dermatology. 201, 37-39.
 - [14] Bowden, G.H.W., Ellwood, D.C., and Hamilton, I.R. (1979) Microbial ecology of the oral cavity. Adv. Microb. Ecol. 3, 135–217.
 - [15] Frandsen, E.V., Pedrazzoli, V., and Kilian, M. (1991) Ecology of viridans streptococci in the oral cavity and pharynx. Oral Microbiol. Immunol. 6, 129–133.
- 20 [16] Sugi-Ikai, N., Nakazawa, M., Nakamura, S., Ohno, S., and Minami, M. (1999) Increased frequencies of interleukin-2 and interferon-gamma producing T cells in patients with active Behçet's disease (BD) and recurrent aphthous stomatitis (RAS). Clin. Exp. Immunol. 118, 451-7.

[17] Frassanito, M.A., Dammacco, R., Cafforio, P., and Dammacco, F. (1999) Th-1 polarization of the immune response in Behçet's disease: a putative pathogenic role of interlukin-12. Arthritis Rheum. 42, 1967-74.

[18] Turan, B., Gallati, H., Erdi, H., Gurler, A., Michel, B.A., and Villiger, P.M. (1997)

- Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Behçet's disease; soluble TNFR-75 as a biological marker of disease activity. J Rheumatol. 24, 128-132.
 - [19] Raziuddin, S., al-Dalaan, A., Bahabri, S., Siraj, A.K., al-Sedairy, S. (1998)Divergent cytokine production profile in Behçet's disease. Altered Th1/Th2 cell

10 cytokine pattern. J Rheumatol. 25, 329-333.

- [20] Lehner T., Lavery E., Smith R., van der Zee R., Mizushima Y., Shinnick T. (1991)
 Association between the 65-kilodalton heat shock protein, *Streptococcus sanguis*, and the corresponding antibodies in Behçet's syndrome. Infect Immun. 59, 1434-1441.
- [21] Direskeneli H, Keser G, D'Cruz D, Khamashta M.A., Akoglu T, Yazici H, Yurdakul S, Hamuryudan V, Ozgun S, Goral A.J. (1995) Anti-endothelial cell antibodies, endothelial proliferation and von Willebrand factor antigen in Behçet's disease.
 Clin Rhuematol. 14, 55-61.

[22] Celet, B., Akman-Demir, G., Serdaroglu, P., Yentur, S.P., Tasci, B., van Noort J.M.,

- Eraksoy, M., Saruhan-Direskeneli, G. (2000) Anti-alpha B-crystallin
 immunoreactivity in inflammatory nervous system diseases. J Neurol. 247, 935 939.
 - [23] Aridogan, B.C., Yildirim, M., Baysal, V., Inaloz, H.S., Baz, K., Kaya, S. (2003)Serum Levels of IL-4, IL-10, IL-12, IL-13 and IFN-gamma in Behçet's disease. J

Dermatol. 30, 602-607.

[24] Misumi, M., Hagiwara, E., Takeno, M., Takeda, Y., Inoue, Y., Tsuji, T., Ueda, A., Nakamura, S., Ohno, S., Ishigatsubo, Y.(2003) Cytokine production profile in patients with Behçet's disease treated with infliximab. Cytokine. 24, 210-218.

			Age when first	
Patient			symptoms	
number	Age	Sex	appeared	First symptoms
1	32	m	20	oral ulcer
2	54	m	49	oral ulcer, EN ^a , arthritis
3	49	f	32	oral ulcer, uveitis
4	32	m	30	uveitis
5	43	f	23	uveitis
6	73	f	60	uveitis
7	79	f	68	EN
8	71	m	43	uveitis
9	68	m	43	oral ulcer, papula
10	52	m	32	oral ulcer
11	45	f	34	oral ulcer, EN, genital ulcer
12	45	m	34	oral ulcer, uveitis
13	64	f	37	uveitis
14	62	f	35	uveitis, EN
15	61	m	23	oral ulcer
16	49	f	33	oral ulcer
17	49	f	33	oral ulcer
18	62	f	37	oral ulcer
19	56	f	32	oral ulcer

Table 1. Historical information of patients with ABD

^aEN; erythema nodosum

Present symptoms except for uveitis	Treatment	ESR ^b	CRP	ASO	Activity
oral ulcer	colchicine	16	+	-	oral ulcer, uveitis
oral ulcer, EN ^a , arthritis, genital ulcer	steroid (instillation), colchicine	-	-	NT ^c	EN
oral ulcer, EN, arthritis	steroid, cyclosporine, colchicine	-	-	-	-
oral ulcer, EN, arthritis, epididymitis	steroid, colchicine	-	-	NT	uveitis
oral ulcer, erythema,	steroid, colchicine	-	-	-	oral ulcer, uveitis
oral ulcer, arthritis	steroid, colchicine	-	-	NT	oral ulcer, uveitis
oral ulcer, EN, arthritis	steroid, colchicine	-	-	NT	oral ulcer, uveitis
oral ulcer, genital ulcer	steroid (instillation), colchicine	-	+	NT	oral ulcer, EN
oral ulcer, EN, arthritis, genital ulcer	colchicine	-	-	NT	oral ulcer
oral ulcer, genital ulcer	(-)	-	-	NT	-
oral ulcer, EN, genital ulcer	cyclosporine, colchicine	-	+	NT	uveitis
oral ulcer, EN	cyclosporine, colchicine	41	+	NT	uveitis
(-)	steroid (active symptoms)	-	+	NT	-
EN	steroid (active symptoms)	-	+	NT	-
oral ulcer	colchicine	-	-	NT	-
oral ulcer	colchicine	16	-	NT	-
oral ulcer, EN	steroid, colchicine	-	-	-	-
oral ulcer, genital ulcer	steroid (instillation), colchicine	-	-	NT	-
oral ulcer, EN	colchicine	28	-	-	EN. uveitis
	oral ulcer oral ulcer, EN ^a , arthritis, genital ulcer oral ulcer, EN, arthritis oral ulcer, EN, arthritis oral ulcer, EN, arthritis oral ulcer, erythema, oral ulcer, erythema, oral ulcer, erythema, oral ulcer, erythema, oral ulcer, enthritis oral ulcer, EN, arthritis oral ulcer oral ulcer, genital ulcer oral ulcer, EN, genital ulcer oral ulcer, EN, genital ulcer oral ulcer, EN (-) EN oral ulcer oral ulcer oral ulcer oral ulcer oral ulcer oral ulcer	oral ulcercolchicineoral ulcer, ENª, arthritis, genital ulcersteroid (instillation), colchicineoral ulcer, EN, arthritissteroid, cyclosporine, colchicineoral ulcer, EN, arthritissteroid, colchicineoral ulcer, erythema,steroid, colchicineoral ulcer, erythema,steroid, colchicineoral ulcer, erythema,steroid, colchicineoral ulcer, erythema,steroid, colchicineoral ulcer, EN, arthritissteroid, colchicineoral ulcer, genital ulcercolchicineoral ulcer, genital ulcercolchicineoral ulcer, EN, genital ulcer(-)oral ulcer, EN, genital ulcercyclosporine, colchicineoral ulcer, ENcyclosporine, colchicine(-)steroid (active symptoms)ENsteroid (active symptoms)oral ulcercolchicineoral ulcer, ENsteroid, colchicineoral ulcer, ENsteroid (active symptoms)oral ulcer, ENsteroid (active symptoms)oral ulcer, ENsteroid, colchicineoral ulcer, ENsteroid, colchicine <td>oral ulcercolchicine16oral ulcer, EN^a, arthritis, genital ulcersteroid (instillation), colchicine-oral ulcer, EN, arthritissteroid, cyclosporine, colchicine-oral ulcer, EN, arthritissteroid, colchicine-oral ulcer, erythema,steroid, colchicine-oral ulcer, erythema,steroid, colchicine-oral ulcer, erythema,steroid, colchicine-oral ulcer, arthritissteroid, colchicine-oral ulcer, genital ulcersteroid, colchicine-oral ulcer, genital ulcercolchicine-oral ulcer, EN, arthritis, genital ulcercolchicine-oral ulcer, genital ulcer(-)-oral ulcer, EN, genital ulcercyclosporine, colchicine-oral ulcer, ENcyclosporine, colchicine-oral ulcer, ENsteroid (active symptoms)-coral ulcer, ENsteroid (active symptoms)-coral ulcercolchicine-oral ulcer, ENsteroid (active symptoms)-oral ulcercolchicine-oral ulcercolchicine-oral ulcer, ENsteroid, colchicine-oral ulcer, g</td> <td>oral ulcercolchicine16+oral ulcer, ENª, arthritis, genital ulcersteroid (instillation), colchicineoral ulcer, EN, arthritissteroid, cyclosporine, colchicineoral ulcer, EN, arthritissteroid, colchicineoral ulcer, erythema,steroid, colchicineoral ulcer, arthritissteroid, colchicineoral ulcer, arthritissteroid, colchicineoral ulcer, genital ulcersteroid (colchicineoral ulcer, genital ulcercolchicineoral ulcer, EN, arthritissteroid (instillation), colchicine-+oral ulcer, genital ulcer(-)oral ulcer, EN, genital ulcercyclosporine, colchicine++oral ulcer, ENcyclosporine, colchicine++oral ulcer, ENcyclosporine, colchicine++oral ulcer, ENcyclosporine, colchicine++oral ulcer, ENcyclosporine, colchicine++oral ulcer, ENsteroid (active symptoms)-+ENsteroid (active symptoms)-+oral ulcercolchicineoral ulcer, ENsteroid, colchicineoral ulcer, ENsteroid, colchicineoral ulcer, ENsteroid, colchicineoral ulcer, ENsteroid, colchicineoral ulcer, ENsteroid, colchicine</td> <td>oral ulcercolchicine16+-oral ulcer, ENª, arthritis, genital ulcersteroid (instillation), colchicineNT°oral ulcer, EN, arthritissteroid, cyclosporine, colchicineNToral ulcer, EN, arthritissteroid, colchicineNToral ulcer, erythema,steroid, colchicineNToral ulcer, arthritissteroid, colchicineNToral ulcer, genital ulcersteroid, colchicineNToral ulcer, genital ulcersteroid (instillation), colchicine-NToral ulcer, genital ulcercolchicineNToral ulcer, EN, arthritissteroid (instillation), colchicine-NToral ulcer, genital ulcercolchicineNToral ulcer, EN, genital ulcercolchicineNToral ulcer, EN, genital ulcercyclosporine, colchicine-NToral ulcer, ENcyclosporine, colchicine-+NToral ulcer, ENsteroid (active symptoms)-+NTENsteroid (active symptoms)-+NToral ulcercolchicineNToral ulcer, ENsteroid (colchicineNToral ulcer, ENsteroid (active symptoms)-+NToral ulcer, ENsteroid, colchicineoral ulcer, ENsteroid (colchicine<td< td=""></td<></td>	oral ulcercolchicine16oral ulcer, EN ^a , arthritis, genital ulcersteroid (instillation), colchicine-oral ulcer, EN, arthritissteroid, cyclosporine, colchicine-oral ulcer, EN, arthritissteroid, colchicine-oral ulcer, erythema,steroid, colchicine-oral ulcer, erythema,steroid, colchicine-oral ulcer, erythema,steroid, colchicine-oral ulcer, arthritissteroid, colchicine-oral ulcer, genital ulcersteroid, colchicine-oral ulcer, genital ulcercolchicine-oral ulcer, EN, arthritis, genital ulcercolchicine-oral ulcer, genital ulcer(-)-oral ulcer, EN, genital ulcercyclosporine, colchicine-oral ulcer, ENcyclosporine, colchicine-oral ulcer, ENsteroid (active symptoms)-coral ulcer, ENsteroid (active symptoms)-coral ulcercolchicine-oral ulcer, ENsteroid (active symptoms)-oral ulcercolchicine-oral ulcercolchicine-oral ulcer, ENsteroid, colchicine-oral ulcer, g	oral ulcercolchicine16+oral ulcer, ENª, arthritis, genital ulcersteroid (instillation), colchicineoral ulcer, EN, arthritissteroid, cyclosporine, colchicineoral ulcer, EN, arthritissteroid, colchicineoral ulcer, erythema,steroid, colchicineoral ulcer, arthritissteroid, colchicineoral ulcer, arthritissteroid, colchicineoral ulcer, genital ulcersteroid (colchicineoral ulcer, genital ulcercolchicineoral ulcer, EN, arthritissteroid (instillation), colchicine-+oral ulcer, genital ulcer(-)oral ulcer, EN, genital ulcercyclosporine, colchicine++oral ulcer, ENcyclosporine, colchicine++oral ulcer, ENcyclosporine, colchicine++oral ulcer, ENcyclosporine, colchicine++oral ulcer, ENcyclosporine, colchicine++oral ulcer, ENsteroid (active symptoms)-+ENsteroid (active symptoms)-+oral ulcercolchicineoral ulcer, ENsteroid, colchicineoral ulcer, ENsteroid, colchicineoral ulcer, ENsteroid, colchicineoral ulcer, ENsteroid, colchicineoral ulcer, ENsteroid, colchicine	oral ulcercolchicine16+-oral ulcer, ENª, arthritis, genital ulcersteroid (instillation), colchicineNT°oral ulcer, EN, arthritissteroid, cyclosporine, colchicineNToral ulcer, EN, arthritissteroid, colchicineNToral ulcer, erythema,steroid, colchicineNToral ulcer, arthritissteroid, colchicineNToral ulcer, genital ulcersteroid, colchicineNToral ulcer, genital ulcersteroid (instillation), colchicine-NToral ulcer, genital ulcercolchicineNToral ulcer, EN, arthritissteroid (instillation), colchicine-NToral ulcer, genital ulcercolchicineNToral ulcer, EN, genital ulcercolchicineNToral ulcer, EN, genital ulcercyclosporine, colchicine-NToral ulcer, ENcyclosporine, colchicine-+NToral ulcer, ENsteroid (active symptoms)-+NTENsteroid (active symptoms)-+NToral ulcercolchicineNToral ulcer, ENsteroid (colchicineNToral ulcer, ENsteroid (active symptoms)-+NToral ulcer, ENsteroid, colchicineoral ulcer, ENsteroid (colchicine <td< td=""></td<>

Table 2. Clinical data of patients with ABD.

^aEN; erythema nodosum, ^bESR; erythrocyte sedimentation rate (mm/hr), ^cNT=not tested

Figure legends

Fig. 1. Chemiluminescence assay with various antigensWhole blood obtained from patients with ABD (n=19) and healthy volunteers (n=21)was stimulated with zymozan and *Streptococcus* antigens. Asterisks (*) indicate

- significantly (p<0.05) lower values than in both the patients and controls stimulated with antigen of strain BD113-20 (a strain isolated from s patient with ABD).
 Fig. 2. IL-8 production by peripheral lymphocytes
 Lymphocytes from the patients (ABD; n=19) and controls (n=21) were stimulated with *S. sanguinis* (ATCC10556 or strain BD113-20) or conA. Asterisks (*) with bars indicate
- 10 significant differences (p<0.05).

Fig. 3. IFN-γ production by peripheral lymphocytes

Fig. 5. IL-10 production by peripheral lymphocytes

Lymphocytes from the patients (ABD; n=19) and healthy controls (n=21) were stimulated with *S. sanguinis* (ATCC10556 or strain BD113-20) or conA. Asterisks (*) with bars indicate significant differences (p<0.05).

Figure 4. IL-12 production from peripheral lymphocytes
 Lymphocytes from the patients (ABD; n=19) and controls (n=21) were stimulated with
 S. sanguinis (ATCC10556 or strain BD113-20) or conA. Asterisks (*) with bars indicate
 significant differences (p<0.05).

20 Lymphocytes from the patients (ABD; n=19) and controls (n=21) were stimulated with *S. sanguinis* (ATCC10556 or strain BD113-20) or conA. Asterisks (*) with bars indicate significant differences (p<0.05).

Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5

